About the company
Algentech specialises in the development of cutting edge technologies for gene editing and synthetic biology tools applications for multi-sectorial applications. The company was incorporated in 2009, is a member of the Genopole BioCluster and performs its R&D activities at the INRA center in Versailles.
Our mission is to solve current technological bottlenecks in the field of genome engineering and bring novel approaches to the market.
Current In house developed products and R&D include the production of enzymes, surfactants and therapeutic compounds in chloroplasts, the development of efficient booster tools for increased efficiency of Crispr/Cas9-based genome editing methods and the induction of cytoplasmic male sterility in selected crops via mitochondria transformation.
Dr Sorokin has more than 20 years’ experience in genetics, agronomy and biotechnology. He obtained his PhD in plant genetics obtained in 1991 from the school of Agronomy in Minsk for his work on wheat and triticale genetics. Prior to founding Algentech he held the position of senior research associate at the Sainsbury Laboratory (Norwich, UK), in charge of technology development and consultant at Plant Bioscience Ltd (Norwich, UK). He is co-inventor on 5 patent families owned by Algentech.
Dr Malcuit holds a PhD in plant virology received in 1998 from the department of genetics, Trinity College (Dublin, Ireland). Dr Malcuit has extensive experience in genetics and biotechnology. Prior to founding Algentech, she held the position of senior research associate at the Sainsbury Laboratory (Norwich, UK), in charge of the programme for functional genomics using VIGS (Virus-Induced Gene Silencing). She is co-inventor on 5 patent families owned by Algentech.
Graduated from Toulouse Business School & Master in finance from Nice University; Director of Investment at Scientipole Capital, formerly Deputy CEO of Nutrivercell. Project manager at Genopole. Site manager in agribusiness
Nathalie Ricoeur Nicolai
PhD in economy; executive director and founder of Scientipole capital, former project manager at Scientipôle Initiative. Former Deputy Director of economic and financial research at CDC IXIS. AMF Certification
Expertise in Agrochemical industry (Hoechst) and Pharmaceutical industry (Sanofi) in operational position (VP for Latin America zone) as well as Corporate (VP for M&A in emerging market). Serial investor within BADGE organisation.
PhD, graduated from Ecole Polytechnique, Paris and Stanford University; electronic engineering with Thales France, headed international R&D programs. Investor and Consultant for BADGE in Paris
IT specialist, graduated from ENSEM (Ecole Nationale Supérieure d’Electricité et de Mécanique) and IAE Paris business school; Secretary General at IEAM Paris
PhD in molecular virology from Jacques Monod Institute, Paris. After completing a post-doc at the Rockefeller University, New York, she joined Algentech in 2011, in charge of chloroplast technology development
PhD in plant molecular biology from Paris XI University, Orsay; Florina joined Algentech in 2011 in charge of genome editing applications
Msc in Biochemistry from Minsk University. Alena joined Algentech in 2011, in charge of the plant transformation platform
Msc in Biochemistry from Caen University; Sandrine joined Algentech in 2016 as a research assistant specialised in molecular biology and tissue culture
John Paul Morris
Bsc Commerce, graduated from Kerala University (India); joined Algentech in 2016, in charge of client relations in India